Characteristic | Polycystic ovary syndrome* | Matched controls |
---|---|---|
Women, no. | 43 506 | 43 506 |
Age, yr, mean | 28.7 | 28.9 |
Health care use, % of women | ||
Admission to hospital | 3.57 | 4.05 |
Emergency department visit | 4.79 | 4.45 |
Physician office visit | 51.31 | 50.08 |
Combined oral contraceptive use | ||
New user,† no. (%) of women | 20 150 (46.32) | 20 278 (46.61) |
Prevalent user,‡ no. (%) of women | 23 356 (53.68) | 23 228 (53.39) |
Prior time on combined oral contraceptives, mean, d | 103 | 103 |
Total time on combined oral contraceptives, mean, d | 201 | 202 |
Number of combined oral contraceptives products used in the past, mean | 0.6 | 0.6 |
Combined oral contraceptive, % of women | ||
Desogestrel, μg ethinyl estradiol | ||
20 | 3.45 | 3.38 |
25 | 0.47 | 0.46 |
30 | 8.39 | 8.31 |
Drospirenone, μg ethinyl estradiol | ||
20 | 7.46 | 8.45 |
30 | 20.81 | 21.02 |
Levonorgestrel, μg ethinyl estradiol | ||
20 | 5.19 | 5.14 |
30 | 3.75 | 3.72 |
Triphasic | 2.35 | 2.11 |
Norethindrone, μg ethinyl estradiol | ||
35 | 10.53 | 10.28 |
Norethindrone acetate, μg ethinyl estradiol | ||
20 | 4.60 | 4.48 |
30 | 2.74 | 2.66 |
35 | 1.51 | 1.55 |
Norgestimate, ethinyl-estradiol μg | ||
25 | 5.78 | 5.68 |
35 | 18.31 | 18.21 |
Norgestrel, μg ethinyl estradiol | ||
30 | 4.66 | 4.55 |
↵* Defined as a claim for polycystic ovary syndrome (International Classification of Disease, 9th Revision [Clinical Modification (ICD-9-CM)] 256.4).
↵† Initiated combined oral contraceptive therapy after the polycystic ovary syndrome claim.
↵‡ Evidence of combined oral contraceptive use during the 365-day period before the polycystic ovary syndrome claim.